Article in Infection and immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Tim J VickersDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
David P BuckleyDepartment of Biochemistry, University of Missouri Columbia, Columbia, Missouri, USA.
Nazia KhatoonDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Alaullah SheikhDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Bipul SetuDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Zachary T BerndsenDepartment of Biochemistry, University of Missouri Columbia, Columbia, Missouri, USA.
James M FleckensteinDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0002-1148-697X
Funding
Infectious Diseases/Basic Microbial Pathogenic MechanismsT32AI007172 · NIAID · WASHINGTON UNIVERSITY · PI Daniel E. Goldberg, JENNIFER A PHILIPS · 1985 to 2026
$13.0M
Novel Antigen Identification for an Enterotoxigenic E. coli VaccineR01AI089894 · NIAID · WASHINGTON UNIVERSITY · PI Zachary T. Berndsen, James Michael Fleckenstein · 2010 to 2026
$7.4M
Molecular Microbiology of Enterotoxigenic E. coli Pathogen-Host InteractionsR01AI126887 · NIAID · WASHINGTON UNIVERSITY · PI FLECKENSTEIN, JAMES MICHAEL · 2016 to 2020
$1.6M
BLRD VA I01 BX001469National Institute of Allergy and Infectious Diseases R01AI089894, R01AI126887National Institute of Allergy and Infectious Diseases T32AI007172NIAID NIH HHS R01 AI089894NIAID NIH HHS R01 AI126887NIAID NIH HHS T32 AI007172U.S. Department of Veterans Affairs 5I01BX001469-05
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Parenteral vaccination with recombinant EtpA glycoprotein impairs enterotoxigenic · full record | OpenQuestion